Disclosure:The HRT Index is an independent comparison resource. We may earn a commission from some links. No drug company paid us to write this page, and affiliate relationships never change the FDA-label facts, safety warnings, or clinical cautions you'll read below.
Elinzanetant FDA Approval Explained: What Lynkuet Treats, What It Costs, and Who Should Ask About It
By The HRT Index Editorial Team · Last verified: · Editorial research, not medical advice.
That's the headline. But the headline leaves out the parts that decide whether it's right for you: the liver blood test you'll need before you start, the roughly $625-a-month price, and how it stacks up against Veozah and hormone therapy. We read the FDA label, the FDA's own review documents, the trial data, and current pricing — so you don't have to dig through 20 tabs.
Who Lynkuet may be a good fit to ask about
| It may fit if… | It's probably not your answer if… |
|---|---|
| Your main problem is moderate-to-severe hot flashes or night sweats | You're mainly bothered by vaginal dryness, painful sex, or bone loss (Lynkuet doesn't treat those) |
| You can't take estrogen, or you simply don't want hormones | You can take hormones and want the strongest possible relief |
| You want a prescription, non-hormonal option backed by recent trials | You're pregnant or might become pregnant without talking to a clinician first |
| You're okay with a baseline liver test and one follow-up at 3 months | You have kidney failure, moderate-to-severe liver problems, a seizure history, or drug interactions your clinician hasn't reviewed |
The 30-second answer (every claim below is sourced)
| Your question | The verified answer | Source |
|---|---|---|
| Is elinzanetant FDA approved? | Yes — approved as Lynkuet for moderate-to-severe menopausal hot flashes and night sweats. | FDA label; DailyMed |
| When? | October 24, 2025. | Bayer announcement |
| Is it a hormone / is it HRT? | No. It's a non-hormonal “neurokinin receptor antagonist.” | DailyMed label |
| What's the dose? | 120 mg once daily at bedtime — two 60 mg capsules, swallowed whole. | DailyMed label |
| What does it cost? | About $625/month without insurance; as little as $25/month for eligible commercially insured patients. | Bayer / Lynkuet cost page |
| Does it have a liver boxed warning like Veozah? | No. FDA reviewed the risk and decided a boxed warning wasn’t warranted at approval. Liver testing is still required. | FDA review documents |
| Is it the same as Veozah? | No. Veozah blocks one brain receptor (NK3); Lynkuet blocks two (NK1 and NK3). Their warnings and monitoring differ. | DailyMed |
Elinzanetant FDA approval explained: what did the FDA actually approve?
The approval covers hot flashes and night sweats that are moderate to severe— the kind that soak your shirt, wake you at 3 a.m., or pull your focus in the middle of a meeting. Bayer makes it, and it became available in U.S. pharmacies in November 2025.
What this approval does NOT mean
- It does not mean Lynkuet treats all menopause symptoms — not vaginal dryness, not low libido, not bone protection.
- It does not mean it's safer or better than hormone therapy for every person.
- It does not remove the need for a clinician to screen you first.
- It does not guarantee your insurance will cover it.
The timeline, in plain English
| When | What happened | Why it matters to you |
|---|---|---|
| 2021–2023 | The main trials (OASIS 1 and OASIS 2) were run. | The evidence behind the approval is recent and real, not decades-old guesswork. |
| May 2024 | Bayer presented the pivotal results at a major OB-GYN conference. | If you saw early “promising new drug” buzz, this is where it came from. |
| October 24, 2025 | The FDA approved it in the U.S. | This is the line between “in development” and “you can actually get it.” |
| November 17, 2025 | The European Union approved it too — with a slightly broader use (both menopause and breast-cancer endocrine therapy). | Useful if you’ve seen conflicting headlines about where it’s available. |
Is Lynkuet a hormone or HRT?
For decades, the most effective treatment for hot flashes has been estrogen — but not everyone can take it. Maybe you have a personal history that makes hormones risky. Maybe a doctor advised against them. Maybe you've read enough headlines to feel uneasy. Whatever the reason, Lynkuet was built for the person who wants relief without hormones.
Here's the trade-off, stated plainly: because Lynkuet is not hormone therapy, it also doesn't do the otherjobs hormones can do. It won't treat vaginal dryness or painful sex. It isn't a bone-protection plan. It's a focused tool for one specific problem — hot flashes and night sweats.
How does elinzanetant work for hot flashes?
Think of your body's temperature control like a thermostat with a comfort zone. During menopause, falling estrogen shrinks that comfort zone, so tiny temperature changes you'd normally never notice suddenly flip the switch. That's a hot flash: the flushing, the sweating, the heat.
The overactive nerve cells behind this are nicknamed KNDy neurons. Two chemical messengers — substance P (which acts on the NK1 receptor) and neurokinin B (which acts on the NK3 receptor) — help drive them. Veozah blocks only NK3. Lynkuet blocks both NK1 and NK3.That second block (NK1) is also thought to be why Lynkuet showed an added benefit for sleep in its trials — a real point of difference we'll come back to.
How well does it work? What the trials showed
The women in these trials weren't borderline cases. To join, they had to be having at least 50 moderate-to-severe hot flashes a week— that's roughly seven or more a day, including the ones that wreck your sleep. Their average age was about 54.
OASIS trial results (from FDA review documents)
| Trial | Timepoint | Lynkuet | Placebo | Difference vs. placebo |
|---|---|---|---|---|
| OASIS 1 | Week 4 | −7.60/day | −4.31/day | −3.29/day (p<0.0001) |
| OASIS 1 | Week 12 | −8.66/day | −5.44/day | −3.22/day (p<0.0001) |
| OASIS 2 | Week 4 | −8.58/day | −5.54/day | −3.04/day (p<0.0001) |
| OASIS 2 | Week 12 | −9.72/day | −6.48/day | −3.24/day (p<0.0001) |
Source: FDA review documents; trials published in JAMA Internal Medicine. Bigger negative numbers = fewer hot flashes per day.
A few honest notes. First, the placebo group improved a lot too — that's normal in hot-flash studies, which is whythe “difference vs. placebo” column is the one that counts. Second, that roughly 3-per-day advantage cleared the bar researchers use for a genuinely meaningful result (at least 2 fewer hot flashes a day versus placebo).
A third, year-long study (OASIS 3) showed the benefit held up across 52 weeks. It also surfaced one safety detail worth knowing: in that longer study, serious side effects were uncommon but happened more often on elinzanetant (4.2%) than on placebo (1.9%). Across the studies, there were no deaths. The takeaway isn't alarm — it's that the long-term safety picture is still being filled in, so it's fair to ask your clinician about it.
How fast does it work?
The trials measured clear results at weeks 4 and 12, and some improvement showed up as early as week 1. By week 12, women on Lynkuet had roughly 65–67% fewer daily moderate-to-severe hot flashes, compared with about 42–46%on placebo. It's not an on/off switch you feel the first night, but it's not a slow crawl either. Ask your clinician how long to give it a fair trial before judging results.
How is Lynkuet different from Veozah?
| Feature | Lynkuet (elinzanetant) | Veozah (fezolinetant) |
|---|---|---|
| Liver boxed warning? | No — FDA reviewed the risk and ruled it wasn’t warranted at approval | Yes — added after liver-injury reports |
| Liver blood tests | Before starting, then once at 3 months | Before starting, then monthly for 3 months, then at 6 and 9 months |
| FDA approval | October 2025 | 2023 |
| Receptors blocked | Two (NK1 + NK3) | One (NK3) |
| Dose | 120 mg nightly (2 capsules) | 45 mg daily |
| Sleep benefit measured in trials | Yes — a secondary benefit | — |
| Main drug interaction | Avoid strong CYP3A4 blockers; no grapefruit | Can’t be used with certain CYP1A2 blockers |
| Most common side effects | Headache, fatigue | Stomach pain, diarrhea, insomnia, back pain |
| Studied in breast-cancer patients on hormone-blocking therapy | Yes (a separate study) | Not studied in this group |
| Rough cash price/month | ~$625 | ~$550–$765 |
Sources: FDA label and FDA review. Last checked .
A “boxed warning” (sometimes called a black-box warning) is the FDA's strongest safety alert. Veozah got one for the risk of liver injury. When the FDA reviewed Lynkuet, it specifically compared the two drugs' chemistry and concluded the liver risk did not rise to the level of a boxed warning at the time of approval. That's stated in the FDA's own review documents. It's also why Lynkuet's liver-testing schedule is lighter: a baseline test, then one recheck at three months, versus Veozah's checks at months 1, 2, 3, 6, and 9.
Lynkuet vs. Veozah vs. Brisdelle vs. hormone therapy: which path fits you?
| Lynkuet (elinzanetant) | Veozah (fezolinetant) | Brisdelle (paroxetine 7.5 mg) | Hormone therapy (estrogen ± progestogen) | |
|---|---|---|---|---|
| Type | Non-hormonal (dual NK1/NK3 blocker) | Non-hormonal (NK3 blocker) | Non-hormonal (low-dose SSRI) | Hormonal |
| FDA approved | 2025 | 2023 | 2013 | Decades; most effective for hot flashes |
| Liver boxed warning | No | Yes | No | No |
| Liver monitoring | Baseline + 3 months | Baseline + 5 checkpoints | Not required | Not required |
| Also helps sleep | Yes (measured benefit) | Less so | Sometimes | Indirectly |
| Best for the person who says… | “I can’t/won’t do hormones, and my nights are rough too” | “I want a non-hormonal NK option” | “I’d like an older, lower-cost non-hormonal choice” | “I can take estrogen and want the strongest relief” |
Brisdelleis worth a sentence on its own: it's a low-dose version of the antidepressant paroxetine, it's been FDA-approved for hot flashes since 2013, and it doesn't require liver monitoring — but it carries the usual considerations that come with an SSRI and isn't right for everyone.
Who should not take Lynkuet, and what to watch for
| Safety issue | What it means in plain English | What to do |
|---|---|---|
| Pregnancy | Lynkuet must not be used in pregnancy; animal studies showed it can cause pregnancy loss. | Your clinician will confirm you’re not pregnant before you start. Use reliable birth control during treatment and for 2 weeks after stopping. |
| Liver testing | You need a liver blood test before starting and again at 3 months. Don’t start if your liver enzymes (ALT or AST) or bilirubin are at least twice the normal limit. | Ask which labs you need and when. Report yellowing skin or eyes, dark urine, nausea, or belly pain right away. |
| Severe kidney disease | If you have kidney failure / end-stage kidney disease (with or without dialysis), Lynkuet is not recommended — it hasn’t been studied in that group. | Tell your clinician about any serious kidney condition. |
| Moderate-to-severe liver problems | Lynkuet is not recommended if you have moderate-to-severe liver impairment. | Share your full liver history. |
| Daytime drowsiness | It can cause sleepiness, fatigue, or dizziness — which is why it’s taken at bedtime. | Don’t drive or do risky tasks until you know how it affects you. |
| Seizure history | The label notes a seizure was reported in one trial patient who had a seizure history. | Tell your clinician if you’ve ever had a seizure. |
| Drug & grapefruit interactions | It’s processed by a liver pathway called CYP3A4. Avoid strong blockers of that pathway (some antifungals, certain antibiotics) and grapefruit. With moderate blockers, the dose drops to 60 mg. | Bring a full list of your medicines and supplements. Skip grapefruit and grapefruit juice. |
Source: FDA label / DailyMed.
Does Lynkuet require liver tests?
This is lighterthan what Veozah requires (which checks at months 1, 2, 3, 6, and 9). The FDA looked hard at Lynkuet's liver risk before approval and decided it didn't warrant a boxed warning. The testing exists to catch a rare problem early — if liver enzymes climb too high, your clinician stops the drug, and in trials those changes were reversible. It's a safety net, not a red flag.
What are Lynkuet's side effects?
Sleepiness and dizziness are common enough — and the reason the pill is taken at night — that you'll want to see how you react before driving. In the year-long study, the list also included abdominal pain, rash, diarrhea, and muscle spasms.
One line we want to be clear about: FDA approval means the drug met the FDA's standards for its approved use based on the evidence submitted. It does not mean “risk-free.”No effective medicine is — and a page that tells you otherwise isn't being straight with you.
What does Lynkuet cost, and will insurance cover it?
| Cost scenario | What to expect | Note |
|---|---|---|
| Cash price (Bayer’s stated price) | ~$625/month | Pharmacy price guides currently list a month’s supply (60 capsules) from around $618. |
| Undiscounted retail | Some trackers have listed it near $1,000/month before savings | This is why checking the savings options matters before you fill. |
| Commercial insurance + manufacturer savings card | As little as $25/month if eligible | Bayer offers this through its pharmacy partner. Eligibility: commercial insurance only. |
| Medicare / Medicaid | Not eligible for the manufacturer copay card | Part D coverage and the 2026 out-of-pocket cap may still help; ask your pharmacist. |
| Can’t afford it at all | A Bayer patient-assistance program may provide it at no cost for those who qualify | Worth asking about directly at the Bayer or Lynkuet website. |
Sources: Bayer / Lynkuet cost page; Drugs.com price guide.
A practical heads-up: some insurance plans use “step therapy,”meaning they'll want you to try a cheaper option before they'll cover Lynkuet. That's not a no — it's a hoop. Knowing it exists helps you plan the conversation with your clinician.
Does the approval cover hot flashes from breast cancer treatment?
| Region | What the approval covers |
|---|---|
| United States (FDA) | Moderate-to-severe hot flashes due to menopause only. Approved October 24, 2025. |
| European Union (EMA) | Moderate-to-severe hot flashes from menopause or from adjuvant endocrine therapy for breast cancer. Authorized November 17, 2025, backed by a 474-woman study. |
Source: European Medicines Agency.
If you have a breast-cancer history, ask your oncology team before assuming Lynkuet applies to your situation. They know your full picture, including how it might interact with your cancer treatment. The label's drug-interaction studies found no meaningful interaction between elinzanetant and tamoxifen — but that's a detail for your oncologist to weigh, not a green light from a website. You can also read more on our HRT and breast cancer risk page.
Where can you actually get Lynkuet?
- Talk to a clinician (in person or by telehealth) about your hot flashes and whether a non-hormonal option fits your situation.
- Get your baseline liver blood test — this is required before starting. Your clinician will order it.
- They send the prescription to a pharmacy — Bayer's delivery partner (BlinkRx) or your local pharmacy.
- You fill it. Through the delivery pharmacy, eligible commercially insured patients can have the savings card applied automatically and the medicine shipped, usually within a few days.
If you've read this far and realized you might actually be a good candidate for hormone therapy instead — because you can take estrogen and want the most effective relief — our comparison of online HRT providers breaks down who fits which option and where to start.
What to ask your clinician before starting Lynkuet
Here's a checklist you can screenshot or print:
About your symptoms
- Are my hot flashes and night sweats moderate to severe enough for prescription treatment?
- Are sleep problems a big part of this for me? (This may favor certain options.)
- Do I also have vaginal dryness or other symptoms a different treatment would handle better?
About safety
- What baseline liver bloodwork do I need, and when is the 3-month recheck?
- Could I be pregnant, and what birth control should I use on this?
- Do any of my current medicines or supplements interact through CYP3A4?
- Does my history — kidney, liver, or seizures — change anything?
About fit and cost
- Would hormone therapy be more effective for me, given my history?
- Will my insurance cover Lynkuet, or will I need to try something first (step therapy)?
- Am I eligible for the savings card or the patient-assistance program?
If you have a breast-cancer history
- Should this question go to my oncology team first?
The bottom line: is Lynkuet worth asking about?
| If you're thinking… | The bottom line |
|---|---|
| “I need a non-hormonal hot-flash option.” | Worth asking about — alongside Veozah and Brisdelle. See our non-hormonal options overview. |
| “I want the strongest, broadest relief and can take estrogen.” | Ask about hormone therapy first; compare providers here. |
| “I had breast cancer or take hormone-blocking therapy.” | Take it to your oncology team before anything else. See our HRT and breast cancer risk page. |
| “I'm worried about liver tests or cost.” | Compare the options before deciding — the quiz helps you frame it. |
| “I honestly don't know which box I'm in.” | Start with the quiz, then bring your questions to a clinician. |
Still not sure which menopause-care path is right for you?
Take our free 60-second matching quiz for a personalized starting point — no email required, no pressure, just clarity.
Take the 60-second quiz →Frequently asked questions
- Is elinzanetant FDA approved?
- Yes. It's FDA-approved under the brand name Lynkuet for moderate-to-severe hot flashes and night sweats due to menopause, as of October 24, 2025.
- What's the brand name for elinzanetant?
- In the U.S., it's sold as Lynkuet, made by Bayer.
- Is Lynkuet a hormone?
- No. It's a non-hormonal drug called a neurokinin (NK1/NK3) receptor antagonist. It contains no estrogen or progesterone.
- What does Lynkuet treat?
- Moderate-to-severe hot flashes and night sweats due to menopause. It does not treat vaginal dryness, low libido, or bone loss.
- How much does Lynkuet cost?
- About $625 a month without insurance. Eligible people with commercial insurance may pay as little as $25 a month through a manufacturer savings program; actual cost depends on your plan.
- Does Lynkuet require liver tests?
- Yes — a liver blood test (ALT, AST, ALP, and bilirubin) before you start and again at 3 months. You shouldn't begin it if your liver enzymes or bilirubin are already at least twice the normal limit.
- Does Lynkuet have a boxed warning like Veozah?
- No. The FDA reviewed the liver risk and decided a boxed warning wasn't warranted at approval. It still requires a liver blood test before starting and again at 3 months.
- Can I take Lynkuet if I have liver or kidney problems?
- It's not recommended if you have moderate-to-severe liver impairment or kidney failure (end-stage kidney disease). Mild kidney or liver issues may be okay — that's a question for your clinician.
- What medicines interact with Lynkuet?
- Avoid strong CYP3A4-blocking medicines (some antifungals and antibiotics) and grapefruit. With moderate CYP3A4 blockers, the dose is reduced to 60 mg. Bring a full medication and supplement list to your clinician.
- Is Lynkuet better than Veozah?
- Not “better” across the board — different. Veozah blocks one receptor (NK3); Lynkuet blocks two (NK1 and NK3), with a measured sleep benefit and a lighter liver-monitoring schedule. Veozah has been available longer. The right pick depends on your situation.
- Can breast-cancer patients take Lynkuet?
- The U.S. approval is for menopausal hot flashes, not specifically for breast-cancer-treatment hot flashes; the EU approval is broader. If you have a breast-cancer history, ask your oncology team first.
- Is Lynkuet approved in Europe for breast-cancer hot flashes?
- Yes — the EU authorized it (November 17, 2025) for hot flashes from menopause or from breast-cancer endocrine therapy. The U.S. approval covers menopause only.
- Is there a generic version of elinzanetant?
- No. As a newly approved branded drug, there is no generic yet.
- How fast does Lynkuet work?
- Clear results showed up at 4 and 12 weeks in trials, with some improvement as early as week 1. Ask your clinician how long to give it a fair trial before judging results.
What we actually verified
Verified from regulators and primary sources (FDA label, FDA review documents, EMA, published trials): the approval and date, the approved use, the 120 mg dose, the warnings and contraindications, the liver-testing rules, the kidney/liver restrictions, the OASIS trial results, the FDA's boxed-warning decision, and the EU's broader indication.
Stated by the manufacturer (Bayer): the $625 cash price, the $25/month commercial-insurance savings program, the delivery-pharmacy workflow, and the patient-assistance program.
Checked against third-party price references (pharmacy price guides): current cash and retail price ranges, which move over time.
Still verify yourself before relying on it: your specific insurance plan's coverage and tier, whether prior authorization or step therapy applies to you, which telehealth providers currently prescribe Lynkuet, and your personal eligibility — that last one is always a clinician's call.
Sources
- U.S. FDA — Lynkuet (elinzanetant) prescribing information / label
- U.S. FDA — Application 219469 review and risk-assessment documents (boxed-warning decision; OASIS efficacy data)
- DailyMed (National Library of Medicine) — LYNKUET (elinzanetant) label
- Bayer — Lynkuet FDA approval announcement and OASIS 1/2 results
- Bayer / Lynkuet — cost and savings information
- European Medicines Agency — Lynkuet (elinzanetant) authorization and indication
- Drugs.com — Lynkuet price guide (for current price verification)
- JAMA Internal Medicine— Elinzanetant for the Treatment of Vasomotor Symptoms (OASIS 1 and 2)
Also on The HRT Index
This article is for general education and is not medical advice. Talk to a licensed clinician about your individual situation before starting, stopping, or changing any treatment. Last updated: .